Literature DB >> 19376392

Endomyocardial biopsy as risk factor in the development of tricuspid insufficiency after heart transplantation.

A I Fiorelli1, G H B Coelho, J L Oliveira, V D Aiello, L A Benvenuti, A Santos, A Chi, A Tallans, M L Igushi, F Bacal, E A Bocchi, N A G Stolf.   

Abstract

OBJECTIVE: Endomyocardial biopsy (EMB), which is used to monitor for rejection, may cause tricuspid regurgitation (TR) after orthotopic heart transplantation (OHT). The purpose of this investigation was to examine the occurrence of tricuspid valve tissue in myocardial specimens obtained by routine EMB performed after OHT. PATIENTS AND METHODS: From January 2000 to July 2008, 125 of the patients who underwent OHT survived more than 1 month. Their follow-up varied from 1 month to 8.5 years (mean, 5.1 +/- 3.7 years). EMB was the gold standard examination and myocardial scintigraphy with gallium served as a screen to routinely monitor rejection.
RESULTS: Each of 428 EMB including 4 to 7 fragments, totaling 1715 fragments, were reviewed for this study. The number of EMB per patient varied from 3 to 8 (mean, 4.6 +/- 3.5). Histopathological analysis of these fragments showed tricuspid tissue in 4 patients (3.2%), among whom only 1 showed aggravation of TR.
CONCLUSIONS: EMB remains the standard method to diagnose rejection after OLT. It can be performed with low risk. Reducing the number of EMB using gallium myocardial scintigraphy or other alternative methods as well as adoption of special care during the biopsy can significantly minimize trauma to the tricuspid valve.

Entities:  

Mesh:

Year:  2009        PMID: 19376392     DOI: 10.1016/j.transproceed.2009.02.011

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Endomyocardial biopsy for monitoring heart transplant patients: 11-years-experience at a german heart center.

Authors:  Thomas Strecker; Johannes Rösch; Michael Weyand; Abbas Agaimy
Journal:  Int J Clin Exp Pathol       Date:  2012-11-20

2.  Feasibility and compliance with daily home electrocardiogram monitoring of the QT interval in heart transplant recipients.

Authors:  Erik V Carter; Kathleen T Hickey; David M Pickham; Lynn V Doering; Belinda Chen; Patricia R E Harris; Barbara J Drew
Journal:  Heart Lung       Date:  2012-03-28       Impact factor: 2.210

Review 3.  Cell-free DNA in the surveillance of heart transplant rejection.

Authors:  Dhruva Sharma; Ganapathy Subramaniam; Neha Sharma; Preksha Sharma
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-02-02

4.  Remote noninvasive allograft rejection monitoring for heart transplant recipients: study protocol for the novel evaluation with home electrocardiogram and remote transmission (NEW HEART) study.

Authors:  Lynn V Doering; Kathleen Hickey; David Pickham; Belinda Chen; Barbara J Drew
Journal:  BMC Cardiovasc Disord       Date:  2012-03-02       Impact factor: 2.298

5.  Cell-free DNA donor fraction analysis in pediatric and adult heart transplant patients by multiplexed allele-specific quantitative PCR: Validation of a rapid and highly sensitive clinical test for stratification of rejection probability.

Authors:  Paula E North; Emily Ziegler; Donna K Mahnke; Karl D Stamm; Angela Thomm; Paul Daft; Mary Goetsch; Huan Ling Liang; Maria Angeles Baker; Adam Vepraskas; Chris Rosenau; Mahua Dasgupta; Pippa Simpson; Michael E Mitchell; Aoy Tomita-Mitchell
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

6.  Functional tricuspid valve insufficiency after cardiac transplantation: Which factor is the most important?

Authors:  Vüsal Hajiyev; Michael Dandel; Ruhi Yeter; Felix Schoenrath; Felix Hennig; Volkmar Falk; Christoph Knosalla
Journal:  JTCVS Open       Date:  2020-08-03

Review 7.  A Meta-Analysis on Prophylactic Donor Heart Tricuspid Annuloplasty in Orthotopic Heart Transplantation: High Hopes from a Small Intervention.

Authors:  Alberto Emanuel Bacusca; Andrei Tarus; Alexandru Burlacu; Mihail Enache; Grigore Tinica
Journal:  Healthcare (Basel)       Date:  2021-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.